Compare SIDU & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | BCYC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.4M | 291.8M |
| IPO Year | 2021 | 2019 |
| Metric | SIDU | BCYC |
|---|---|---|
| Price | $2.07 | $3.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 5.8M | 332.7K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,383,878.00 | N/A |
| Revenue This Year | $171.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $3.75 |
| 52 Week High | $6.79 | $9.16 |
| Indicator | SIDU | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 43.08 |
| Support Level | $2.00 | $3.94 |
| Resistance Level | $3.12 | $4.52 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 73.28 | 33.90 |
Sidus Space Inc is a space and defense technology company with core capabilities that include dual use satellite manufacturing & technology integration, AI products and services, space and defense hardware components and space-based data solutions. The company generates revenue through a combination of: Satellite platform sales and customization, Payload hosting and mission services, Engineering and systems integration services, and Space and defense hardware manufacturing. The firm supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers. The firm generates revenue principally from satellite platform and payload hosting contracts, manufacturing and engineering services, mission operations, and sales of proprietary hardware products.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.